lung cancer
Lung cancer vaccine dropped
April 2, 2014Research and Development, Sales and Marketing GSK, MAGE-A3, NSCLC, Vaccine, lung cancer, magrit
GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …
Pfizer’s Xalkori impresses in new setting
March 26, 2014Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer
Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …
Endocyte lung cancer drug shows promise
March 24, 2014Research and Development, Sales and Marketing Endocyte, MSD, NSCLC, lung cancer, vintafolide
Endocyte and partner MSD have released positive mid-stage trial results for their investigational lung cancer drug vintafolide. The treatment met …
GSK cancer vaccine fails again
March 20, 2014Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma
GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials. The …
New online tool to hear lung cancer patients’ stories
October 29, 2013Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer
The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …
Price cut not enough for Pfizer’s Xalkori
August 16, 2013Sales and Marketing NICE, Pfizer, Xalkori, lung cancer
In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …
Phoenix from the flames for Lilly cancer drug
August 14, 2013Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab
A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …
Funding boost for lung cancer ‘map’
July 18, 2013Research and Development, Sales and Marketing cancer research, lung cancer, tracerx
A new Cancer Research UK study aims to unlock lung cancer’s secrets by tracking how lung tumours develop and evolve …
FDA approves Boehringer’s lung cancer drug
July 12, 2013Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer
Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
Roche’s Lung cancer test approved for Europe
December 5, 2011Research and Development, Sales and Marketing Roche, Tarceva, lung cancer
A new test which should help to better target treatment of patients with non-small cell lung cancer (NSCLC) has received …
Cephalon buys Gemin X for $225 million
March 24, 2011Research and Development Cephalon, lung cancer
Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
Digital Pharma: Merck Serono launches campaign for cancer carers
February 4, 2011Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer
Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …
Roche set to challenge NICE Tarceva decision
November 25, 2010Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer
NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
